Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Capricor Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CAPR
Nasdaq
2836
www.capricor.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Capricor Therapeutics, Inc.
US High Growth Tech Stocks with Promising Potential
- Jun 30th, 2025 5:45 am
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
- Jun 26th, 2025 7:49 am
No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital
- Jun 25th, 2025 10:15 am
Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright
- Jun 25th, 2025 9:05 am
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
- Jun 24th, 2025 7:00 am
Capricor Therapeutics announces four-year data from HOPE-2 OLE study
- Jun 21st, 2025 7:30 am
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
- Jun 20th, 2025 7:25 am
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
- Jun 17th, 2025 7:00 am
Capricor says FDA inspection brought Form 483 with several observations
- Jun 12th, 2025 7:35 am
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
- Jun 11th, 2025 7:25 am
Exploring 3 High Growth Tech Stocks In The US Market
- May 22nd, 2025 11:38 am
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential
- May 21st, 2025 9:22 am
Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results
- May 16th, 2025 4:20 am
Capricor Therapeutics First Quarter 2025 Earnings: US$0.53 loss per share (vs US$0.31 loss in 1Q 2024)
- May 15th, 2025 4:16 am
Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
- May 14th, 2025 1:15 am
Capricor: Q1 Earnings Snapshot
- May 13th, 2025 2:19 pm
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- May 13th, 2025 2:05 pm
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
- May 13th, 2025 7:00 am
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
- May 7th, 2025 12:53 pm
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
- May 6th, 2025 7:15 am
Scroll